Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Pre-Market Trading 11-05 08:51:07 EST

5.42

+0.09

+1.69%

盘前5.75

+0.33+6.09%

08:50 EST

High5.67	Low5.18	Vol1.42M
Open5.31	D1 Closing5.33	Amplitude9.19%
Mkt Cap172.97M	Tradable Cap87.79M	Total Shares31.91M
T/O7.69M	T/O Rate8.76%	Tradable Shares16.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":5.42,"timestamp":1730754000000,"preClose":5.33,"halted":0,"volume":1418201,"hourTrading":{"tag":"盘前","latestPrice":5.75,"preClose":5.42,"latestTime":"08:50 EST","volume":115,"amount":665.2499760000001,"timestamp":1730814644510},"delay":0,"floatShares":16197842,"shares":31913887,"eps":-1.142393,"marketStatus":"Pre-Market Trading","change":0.09,"latestTime":"11-05 08:51:07 EST","open":5.31,"high":5.67,"low":5.18,"amount":7692580.336582,"amplitude":0.091932,"askPrice":5.75,"askSize":174,"bidPrice":5.3,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.142393,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1730817000000},"marketStatusCode":1,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":5.42,"preHourTrading":{"tag":"盘前","latestPrice":5.75,"preClose":5.42,"latestTime":"08:50 EST","volume":115,"amount":665.2499760000001,"timestamp":1730814644510},"postHourTrading":{"tag":"盘后","latestPrice":5.38,"preClose":5.42,"latestTime":"18:55 EST","volume":293,"amount":1576.5137,"timestamp":1730764550953},"volumeRatio":1.876310452847464,"impliedVol":1.4492,"impliedVolPercentile":0.2589},"requestUrl":"/m/hq/s/SGMT/tweets","defaultTab":"tweets","newsList":[{"id":"2480869766","title":"Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2480869766","media":"Blockhead","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480869766?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:08","pubTimestamp":1730491729,"startTime":"0","endTime":"0","summary":"Madrigal stock catapulted again Friday after Novo Nordisk published not \"game-changing\" results for its MASH treatment.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2024/03/Stock-MadrigalPharmaceuticals-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/03/Stock-MadrigalPharmaceuticals-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/madrigal-stock-novo-nordisk-mash-treatment-rezdiffra/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0198837287.USD","LU0079474960.USD","ETNB","LU0006306889.USD","IE00BJJMRZ35.SGD","BK4007","BK4581","BK4585","LU1093756168.USD","LU0943347566.SGD","LU0689472784.USD","LU0354030511.USD","LU1064131342.USD","NVO","LU0672654240.SGD","IE00BZ1G4Q59.USD","BK4139","LU1023059063.AUD","LU0256863902.USD","LU0471298777.SGD","IE00BK4W5M84.HKD","LU1057294990.SGD","GB00BDT5M118.USD","MDGL","LU0289739699.SGD","LU1035775433.USD","LU0061475181.USD","SGMT","VKTX","IE0009355771.USD","LU0354030438.USD","LU0385154629.USD","LU0203201768.USD","LU0708995401.HKD","IE00B1BXHZ80.USD","BK4516","BK4588","LU0823416689.USD","LU0882574055.USD","LU0122379950.USD","LU0320765059.SGD","IE0002141913.USD","LU0154236417.USD","LU1061106388.HKD","LU1093756325.SGD","BK4532","LU1069344957.HKD","IE00BJLML261.HKD"],"gpt_icon":1},{"id":"2479770845","title":"Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2479770845","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479770845?lang=en_us&edition=fundamental","pubTime":"2024-10-31 17:49","pubTimestamp":1730368140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 05:49 ET (09:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2479736813","title":"Sagimet Biosciences’ Denifanstat: Promising Phase 3 Prospects and Strong Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2479736813","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479736813?lang=en_us&edition=fundamental","pubTime":"2024-10-31 00:05","pubTimestamp":1730304316,"startTime":"0","endTime":"0","summary":"Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping the price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-denifanstat-promising-phase-3-prospects-and-strong-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-denifanstat-promising-phase-3-prospects-and-strong-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2479700864","title":"BRIEF-Sagimet Biosciences Announces Successful Completion Of End-Of-Phase 2 Interactions With FDA On The Development Of Denifanstat For Mash Phase 3 Program Initiation Expected By End Of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479700864","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479700864?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:16","pubTimestamp":1730200602,"startTime":"0","endTime":"0","summary":"Oct 29  - Sagimet Biosciences Inc   :   * SAGIMET BIOSCIENCES ANNOUNCES SUCCESSFUL COMPLETION OF END-OF-PHASE 2 INTERACTIONS WITH FDA ON THE DEVELOPMENT OF DENIFANSTAT FOR MASH; PHASE 3 PROGRAM INITIATION EXPECTED BY END OF 2024Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2479547090","title":"Sagimet Biosciences completes End-of-Phase 2 meeting with FDA on denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2479547090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479547090?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:05","pubTimestamp":1730199912,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced the completion of end-of-Phase 2 interactions with the U.S. Food and Drug Administration, supporting the advan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-completes-end-of-phase-2-meeting-with-fda-on-denifanstat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-completes-end-of-phase-2-meeting-with-fda-on-denifanstat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2479477394","title":"Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479477394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479477394?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:00","pubTimestamp":1730199600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA4HBB0K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2479477179","title":"Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479477179","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479477179?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:00","pubTimestamp":1730199600,"startTime":"0","endTime":"0","summary":"The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the safety and efficacy of denifanstat in patients w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/29/2970662/0/en/Sagimet-Biosciences-Announces-Successful-Completion-of-End-of-Phase-2-Interactions-with-FDA-on-the-Development-of-Denifanstat-for-MASH-Phase-3-Program-Initiation-Expected-by-End-of.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2476241393","title":"Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2476241393","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476241393?lang=en_us&edition=fundamental","pubTime":"2024-10-19 03:10","pubTimestamp":1729278617,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a \"Strong Buy\" rating.Denifanstat's un","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213293784/image_1213293784.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213293784/image_1213293784.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4727708-sagimet-soars-fda-breakthrough-therapy-designation-and-lancet-review-validate-denifanstat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2475596188","title":"Sagimet Biosciences to present Phase 2b data of denifanstat at AASLD 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475596188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475596188?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:20","pubTimestamp":1729077621,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences announced that Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase inhibitor, denifanstat, and pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-to-present-phase-2b-data-of-denifanstat-at-aasld-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-to-present-phase-2b-data-of-denifanstat-at-aasld-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2475462965","title":"Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475462965","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475462965?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:00","pubTimestamp":1729076400,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Oct.  16, 2024  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctiona","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/16/2963912/0/en/Sagimet-Biosciences-Announces-Upcoming-Presentations-at-AASLD-The-Liver-Meeting-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2474014671","title":"Sagimet gains on peer-reviewed data for lead asset in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2474014671","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474014671?lang=en_us&edition=fundamental","pubTime":"2024-10-11 23:41","pubTimestamp":1728661262,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences  traded higher on Friday after announcing that the medical journal The Lancet has published data from a mid-stage trial for its lead asset, denifanstat, targeted at a liver condition called metabolic-dysfunction-associated steatohepatitis . The results published in The Lancet Gastroenterology & Hepatology relate to the company’s Phase 2b FASCINATE-2 clinical trial, which has already reached the primary and several secondary endpoints.  In January, the San Mateo, California-based biotech more than doubled in value after the company announced its topline data.  “Our publication in this esteemed Lancet journal validates the importance of these findings and reinforces the potential impact of denifanstat,” CEO Dave Happel remarked. The company plans to advance the candidate into Phase 3 development next year, Happel added.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212682537/image_1212682537.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212682537/image_1212682537.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4157944-sagimet-stock-gains-lancet-publication","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2474605590","title":"Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2474605590","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474605590?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:41","pubTimestamp":1728646909,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences  said Friday that its experimental drug, denifanstat, used to treat certain metabolic-dysfunction-associated steatohepatitis patients, met its primary and secondary endpoints in a phase 2b study.The study showed that patients treated with the denifanstat showed statistically significant and clinically meaningful improvements in disease activity, MASH resolution, and fibrosis compared to placebo.The company said it plans to start its phase 3 study of the drug this year.Shares of the company rose more than 3% in premarket activity.Price: 4.2900, Change: +0.15, Percent Change: +3.62","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2474406445","title":"Sagimet Biosciences Inc - Denifanstat Shows Significant Improvements in Mash Resolution and Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2474406445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474406445?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:00","pubTimestamp":1728644400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUAC0BPDP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2474116064","title":"Sagimet Biosciences Announces Publication of Results From Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Mash in the Lancet Gastroenterology & Hepatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2474116064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474116064?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:00","pubTimestamp":1728644400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUAC0BPDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2474064453","title":"Sagimet Biosciences Inc - Results Support Advancement of Denifanstat Into Phase 3 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2474064453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474064453?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:00","pubTimestamp":1728644400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUAC0BPDP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2474064232","title":"Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology","url":"https://stock-news.laohu8.com/highlight/detail?id=2474064232","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474064232?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:00","pubTimestamp":1728644400,"startTime":"0","endTime":"0","summary":"- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results support advancement of denifanstat i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/11/2961935/0/en/Sagimet-Biosciences-Announces-Publication-of-Results-from-Phase-2b-FASCINATE-2-Clinical-Trial-of-Denifanstat-in-Biopsy-Confirmed-F2-F3-MASH-in-The-Lancet-Gastroenterology-Hepatolog.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4161","ITT","BK4090","LU0054578231.USD","BK4153","SGMT","LU0053671581.USD","TG"],"gpt_icon":0},{"id":"2472768989","title":"Sagimet Biosciences’ Denifanstat Receives Buy Rating on FDA’s BTD and Promising Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2472768989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472768989?lang=en_us&edition=fundamental","pubTime":"2024-10-04 14:39","pubTimestamp":1728023964,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has maintained their bullish stance on SGMT stock, giving a Buy rating on October 2. Thomas Smith has given h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-denifanstat-receives-buy-rating-on-fdas-btd-and-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/sagimet-biosciences-denifanstat-receives-buy-rating-on-fdas-btd-and-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2472983376","title":"3 Penny Stocks to Watch Now, 10/3/24","url":"https://stock-news.laohu8.com/highlight/detail?id=2472983376","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472983376?lang=en_us&edition=fundamental","pubTime":"2024-10-03 17:46","pubTimestamp":1727948812,"startTime":"0","endTime":"0","summary":"Indonesia Energy, Sagimet Biosciences, and EON Resources are the 3 Penny Stocks to watch on October 3, 2024, based on TipRanks’ Penny Stock Sc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-10-3-24?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-10-3-24?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2472354934","title":"Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2472354934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472354934?lang=en_us&edition=fundamental","pubTime":"2024-10-02 19:23","pubTimestamp":1727868180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 02, 2024 07:23 ET (11:23 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2472543813","title":"Buy Rating for Sagimet Biosciences on Strong Phase 2b Results and Favorable Valuation Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2472543813","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472543813?lang=en_us&edition=fundamental","pubTime":"2024-10-02 18:27","pubTimestamp":1727864858,"startTime":"0","endTime":"0","summary":"Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report). The associated p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-sagimet-biosciences-on-strong-phase-2b-results-and-favorable-valuation-model?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-sagimet-biosciences-on-strong-phase-2b-results-and-favorable-valuation-model?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":-0.0952},{"period":"1month","weight":0.3252},{"period":"3month","weight":0.9152},{"period":"6month","weight":0.2207},{"period":"1year","weight":0.3284},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}